ArticleMolecular carcinogenesis2026
TTK Overexpression as a Prognostic Indicator and Immune Modulator in Kidney Renal Clear Cell Carcinoma.
Article in Molecular carcinogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Kidney renal clear cell carcinoma (KIRC) is a highly aggressive and heterogeneous malignancy characterized by poor clinical outcomes and limited reliable prognostic biomarkers. This study performed a comprehensive bioinformatic analysis to evaluate the clinical and biological significance of threonine-tyrosine kinase (TTK/Mps1) in KIRC. Transcriptomic analyses demonstrated significant overexpression of TTK in tumor tissues, which was strongly associated with advanced stage, metastatic progression, and reduced patient survival. Multivariate regression confirmed TTK as an independent prognostic indicator with high diagnostic accuracy. Network and enrichment analyses revealed that TTK is embedded within a tightly connected mitotic regulatory module, primarily involving spindle assembly checkpoint signaling, G2/M transition control, and chromosome segregation processes. Key co-expressed genes included BUB1, CCNB1, CDK1, and CENPF, indicating a coordinated proliferative program. Pathway analysis further showed strong positive associations with oncogenic cell-cycle signatures and negative correlations with metabolic pathways. Immune profiling indicated that elevated TTK expression correlates with increased immune infiltration and is associated with alterations in the tumor microenvironment. Collectively, these findings suggest that TTK is associated with prognosis and may serve as a potential biomarker in KIRC, with its therapeutic relevance requiring further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.